REPL
Replimune Group, Inc.NASDAQHealthcare$8.41+10.51%ClosedMarket Cap: $694.4M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.68
P/S
0.00
EV/EBITDA
-2.09
DCF Value
$0.33
FCF Yield
-40.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-102.7%
ROA
-94.4%
ROIC
-113.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2026 | $0.00 | NaN% | $-71.9M | $-70.9M | $-0.77 | — |
| Q2 2026 | $0.00 | NaN% | $-84.3M | $-83.1M | $-0.90 | — |
| Q1 2026 | $0.00 | NaN% | $-90.4M | $-86.7M | $-0.95 | — |
| Q4 2025 | $0.00 | -Infinity% | $-79.9M | $-74.1M | $-0.96 | — |
| FY 2025 | $0.00 | NaN% | $-261.6M | $-247.3M | $-3.07 | — |
| Q3 2025 | $0.00 | NaN% | $-66.0M | $-66.3M | $-0.79 | — |
| Q2 2025 | $0.00 | NaN% | $-58.9M | $-53.1M | $-0.68 | — |
| Q1 2025 | $0.00 | NaN% | $-57.4M | $-53.8M | $-0.78 | — |
| Q4 2024 | $0.00 | NaN% | $-58.8M | $-55.1M | $-0.90 | — |
| FY 2024 | $0.00 | NaN% | $-234.8M | $-215.8M | $-3.24 | — |
| Q3 2024 | $0.00 | NaN% | $-56.5M | $-51.1M | $-0.77 | — |
| Q2 2024 | $0.00 | NaN% | $-63.8M | $-60.0M | $-0.90 | — |